Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in J Clin Psychopharmacol Retrieve available abstracts of 124 articles: HTML format

Single Articles

January 2025
1. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
   Clozapine Dosage in Treatment-Refractory Schizophrenia: A Reply to Dr Grover and Colleagues.
   J Clin Psychopharmacol. 2025 Jan 14. doi: 10.1097/JCP.0000000000001955.
   PubMed    
   
   
   
2. OLMOS I, Ricciardi C, Mato M, Guevara N, et al
   Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia.
   J Clin Psychopharmacol. 2025;45:20-27.
   PubMed     Abstract available
   
   
   December 2024
3. EL JABIRY SE, Benkarroum F, Barrimi M, Elghazouani F, et al
   Risperidone-Associated Stuttering in Patient With Schizophrenia: A Case Report.
   J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001950.
   PubMed    
   
   
   
4. HOOBERMAN AJ, Martinez NJ, Stojcevski M, Wechsler B, et al
   A Case of Tacrolimus-Associated Psychosis.
   J Clin Psychopharmacol. 2024 Dec 31. doi: 10.1097/JCP.0000000000001956.
   PubMed    
   
   
   
5. BUESKING SC, Kriz CR, Jarvis SP, Nelson LA, et al
   Recognition of Clozapine-Associated Eosinopenia in Patients With Treatment-Resistant Schizophrenia: A Report of 3 Cases and Literature Review.
   J Clin Psychopharmacol. 2024 Dec 17. doi: 10.1097/JCP.0000000000001947.
   PubMed    
   
   
   
6. TAKEUCHI H, Uchida H
   Efficacy and Safety of Dose Increase From 40 mg/d to 80 mg/d of Lurasidone in Patients With Schizophrenia: A Post Hoc Analysis of Extension Trial.
   J Clin Psychopharmacol. 2024 Dec 2. doi: 10.1097/JCP.0000000000001943.
   PubMed     Abstract available
   
   
   November 2024
7. O'CONNELL P, Alsaffar M
   The Treatment of Iatrogenic Anorgasmia in a Male Patient on Clozapine for Treatment-Resistant Schizophrenia: The Role of Pseudoephedrine.
   J Clin Psychopharmacol. 2024 Nov 12. doi: 10.1097/JCP.0000000000001930.
   PubMed    
   
   
   October 2024
8. PEREZ-SAGASETA DE ILURDOZ I, Aparicio-Dominguez A, Yelmo-Cruz S, Cardenes-Moreno C, et al
   alpha-PVP Associated Psychosis: A Case Report.
   J Clin Psychopharmacol. 2024 Oct 11. doi: 10.1097/JCP.0000000000001918.
   PubMed    
   
   
   September 2024
9. MITOMA R, Hirano S, Nakao T
   Successful Management of ECT-Resistant Interictal Psychosis With Clozapine: A Case Report.
   J Clin Psychopharmacol. 2024;44:527-528.
   PubMed    
   
   
   
10. DI LISI A, Pupo S, Menchetti M, Pelizza L, et al
    Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice.
    J Clin Psychopharmacol. 2024;44:502-508.
    PubMed     Abstract available
    
    
    
11. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
    Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking.
    J Clin Psychopharmacol. 2024;44:492-501.
    PubMed     Abstract available
    
    
    August 2024
12. BUCHANAN RW, Werkheiser AE, Michel H, Zaranski J, et al
    Prebiotic Treatment in People With Schizophrenia.
    J Clin Psychopharmacol. 2024 Aug 16. doi: 10.1097/JCP.0000000000001899.
    PubMed     Abstract available
    
    
    July 2024
13. HAUSER RA, Barkay H, Fernandez HH, Jimenez-Shahed J, et al
    Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    J Clin Psychopharmacol. 2024;44:386-396.
    PubMed     Abstract available
    
    
    
14. GOUDA M, Abe M, Watanabe Y, Kato TA, et al
    Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association.
    J Clin Psychopharmacol. 2024;44:378-385.
    PubMed     Abstract available
    
    
    
15. PACILIO RM, Dalack GW
    Asthma and Atypical Antipsychotics: A Systematic Literature Review and Case Report of Respiratory Side Effects With Lurasidone, Cariprazine, and Lumateperone.
    J Clin Psychopharmacol. 2024;44:436-437.
    PubMed    
    
    
    May 2024
16. KARAL BN, Ozdemir YE, Karayagmurlu A
    The Management of Very Early-Onset Schizophrenia With an Olanzapine and Amisulpride Combination.
    J Clin Psychopharmacol. 2024 May 2. doi: 10.1097/JCP.0000000000001853.
    PubMed    
    
    
    
17. OKADA Y, Inada K, Akazawa M
    Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
    J Clin Psychopharmacol. 2024;44:263-271.
    PubMed     Abstract available
    
    
    
18. DE LEON J
    Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research.
    J Clin Psychopharmacol. 2024;44:212-219.
    PubMed     Abstract available
    
    
    April 2024
19. SCALA M, Martinez Trapote P, Rodriguez-Jimenez R, Pecorino B, et al
    Managing a Treatment-Resistant Schizophrenia Spectrum Disorder With a Hormonal Twist in a Female Patient: A Case Report of a Progestin-Only Pill.
    J Clin Psychopharmacol. 2024 Apr 9. doi: 10.1097/JCP.0000000000001836.
    PubMed    
    
    
    March 2024
20. KORKMAZ SA, Koca E, Yilmaz O, Ozbek T, et al
    Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
    J Clin Psychopharmacol. 2024 Mar 5. doi: 10.1097/JCP.0000000000001837.
    PubMed     Abstract available
    
    
    
21. NAGANO M, Susuta Y, Masui H, Watanabe Y, et al
    Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    J Clin Psychopharmacol. 2024;44:107-116.
    PubMed     Abstract available
    
    
    February 2024
22. MORI Y, Watanabe K, Suzuki Y, Ono H, et al
    Clozapine-Associated Myocarditis in a Patient With Schizophrenia Taking Lemborexant: A Case Report.
    J Clin Psychopharmacol. 2024 Feb 8. doi: 10.1097/JCP.0000000000001817.
    PubMed    
    
    
    
23. DIMA A, Abdelsamie A, Clark-Castillo R, Webb-Wilson H, et al
    Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
    J Clin Psychopharmacol. 2024 Feb 5. doi: 10.1097/JCP.0000000000001819.
    PubMed    
    
    
    January 2024
24. WATANABE M, Misawa F, Takeuchi H
    Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
    J Clin Psychopharmacol. 2024 Jan 26. doi: 10.1097/JCP.0000000000001804.
    PubMed     Abstract available
    
    
    
25. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Reply to a Letter to the Editors From Dr de Souza and colleagues: "Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity".
    J Clin Psychopharmacol. 2024;44:76-78.
    PubMed    
    
    
    
26. DE SOUZA JUNIOR SA, Cavalcante da Rocha ME, Marques Andrade AG, Fernandes de Moraes CL, et al
    Unraveling the Optimal Treatment Approach for Depression in Schizophrenia Spectrum: A Quest for Clarity.
    J Clin Psychopharmacol. 2024;44:74-76.
    PubMed    
    
    
    
27. MOHAMMAD-GHOLIZAD F, Karimzadeh I, Moghimi-Sarani E, Arshadi M, et al
    Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial
    J Clin Psychopharmacol. 2024;44:9-15.
    PubMed     Abstract available
    
    
    
28. KARACAM DOGAN M, Yildiz FG, Temucin CM, Ertugrul A, et al
    Effects of Clozapine on Cortical Inhibition: A Transcranial Magnetic Stimulation Follow-up Study.
    J Clin Psychopharmacol. 2024;44:16-24.
    PubMed     Abstract available
    
    
    November 2023
29. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Reply to Dr Yucel's Comments on the Article "Long-term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555-556.
    PubMed    
    
    
    
30. YUCEL A
    Critical Feedback on Article by Lee and Colleagues: "Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia".
    J Clin Psychopharmacol. 2023;43:555.
    PubMed    
    
    
    
31. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis?: A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023;43:551-553.
    PubMed    
    
    
    
32. MAGISTRI C, Mellini C
    Clozapine-Associated Agranulocytosis: A Systematic Review. Is It Really So Frighteningly Common?
    J Clin Psychopharmacol. 2023;43:527-533.
    PubMed     Abstract available
    
    
    
33. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis: A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023;43:511-513.
    PubMed     Abstract available
    
    
    September 2023
34. KINDT H, Mahgoub Y
    Should We Be Prescribing Stimulants to Patients With Multiple Sclerosis? A Case Report of Stimulant-Associated Psychosis.
    J Clin Psychopharmacol. 2023 Sep 29. doi: 10.1097/JCP.0000000000001766.
    PubMed    
    
    
    
35. CONATY O, Doherty AM, Lally J
    Severe Alprazolam Withdrawal With Delirium and Psychosis. A Case Report and Literature Review.
    J Clin Psychopharmacol. 2023 Sep 7. doi: 10.1097/JCP.0000000000001758.
    PubMed     Abstract available
    
    
    
36. TKACH N, Opler DJ
    A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023;43:481-482.
    PubMed    
    
    
    
37. DE LIMA DN JR, Frota IJ, Macedo DS, Sanders LLO, et al
    Alpha Lipoic Acid for Schizophrenia: Future Investigations With Low Doses and Treatment-Resistant Patients-Reply to Letter by Kishi and Colleagues.
    J Clin Psychopharmacol. 2023;43:478-479.
    PubMed    
    
    
    
38. KISHI T, Sakuma K, Miura G, Ito Y, et al
    Alpha Lipoic Acid for Schizophrenia: A Systematic Review and Meta-analysis.
    J Clin Psychopharmacol. 2023;43:477-478.
    PubMed    
    
    
    
39. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023;43:472-474.
    PubMed    
    
    
    
40. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023;43:468-469.
    PubMed    
    
    
    August 2023
41. JOGI L, Subu O, Jaishankar P, Kumar V, et al
    Management of Treatment-Resistant Schizophrenia in a Patient With Epilepsy With Add on Low-Dose Clozapine-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001737.
    PubMed    
    
    
    
42. BROTHWOOD PL, Husain M, Pinson J, Oloyede E, et al
    Clozapine in Combination With Olanzapine Long-Acting Injection: The Intersection of Treatment-Resistant Schizophrenia and Poor Medication Adherence-A Case Report.
    J Clin Psychopharmacol. 2023 Aug 8. doi: 10.1097/JCP.0000000000001746.
    PubMed    
    
    
    
43. TKACH N, Opler DJ
    Letter to the Editors: A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis.
    J Clin Psychopharmacol. 2023 Aug 7. doi: 10.1097/JCP.0000000000001743.
    PubMed    
    
    
    July 2023
44. RODIN I, Evans A
    Case of Clozapine-Associated Negative Myoclonus.
    J Clin Psychopharmacol. 2023;43:386-387.
    PubMed    
    
    
    May 2023
45. ONITSUKA T, Okada T, Hasegawa N, Tsuboi T, et al
    Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
    J Clin Psychopharmacol. 2023 May 23. doi: 10.1097/JCP.0000000000001704.
    PubMed     Abstract available
    
    
    
46. 
    Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses: Erratum.
    J Clin Psychopharmacol. 2023;43:304.
    PubMed    
    
    
    
47. STREIFF RA
    Institutional Neglect of Anosognosia Is a Critical Barrier in the Treatment of Psychosis Related Disorders.
    J Clin Psychopharmacol. 2023;43:200-203.
    PubMed    
    
    
    April 2023
48. KJELBY E, Gjestad R, Fathian F, Sinkeviciute I, et al
    Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
    J Clin Psychopharmacol. 2023 Apr 22. doi: 10.1097/JCP.0000000000001679.
    PubMed     Abstract available
    
    
    
49. MALHAM KM, Miller BJ
    Long-Acting Injectable Antipsychotics and Infections in Schizophrenia.
    J Clin Psychopharmacol. 2023 Apr 18. doi: 10.1097/JCP.0000000000001694.
    PubMed     Abstract available
    
    
    March 2023
50. LEE MA, Cola P, Jayathilake K, Meltzer HY, et al
    Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Mar 29. doi: 10.1097/JCP.0000000000001671.
    PubMed     Abstract available
    
    
    
51. MALALI METIN H, Aksu T, Akyildiz UO, Sevincok L, et al
    Cerebellar Cognitive Affective Syndrome and Delusional Disorder Associated With Long-Term Phenytoin Use: A Case Report.
    J Clin Psychopharmacol. 2023;43:184-186.
    PubMed    
    
    
    February 2023
52. OLIVOLA M, Arienti V, Bassetti N, Giovanna G, et al
    Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001662.
    PubMed     Abstract available
    
    
    
53. BOGERS JPAM, Schulte PFJ, Broekman TG, de Haan L, et al
    Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001657.
    PubMed     Abstract available
    
    
    
54. LAGREULA J, Ferraiolo M, De Timary P, Delatte B, et al
    Impact of a Caffeine Restriction Policy on Inpatients With Schizophrenia: A Pre-Post Comparison Using Electronic Health Records.
    J Clin Psychopharmacol. 2023 Feb 27. doi: 10.1097/JCP.0000000000001670.
    PubMed     Abstract available
    
    
    
55. ARMSTRONG AG, Preskorn SH
    Thoughts on the Value of Case Series in the Literature: An Example Using the Article on Lurasidone Augmentation of Clozapine in Refractory Schizophrenia.
    J Clin Psychopharmacol. 2023 Feb 24. doi: 10.1097/JCP.0000000000001676.
    PubMed    
    
    
    
56. TIRUPATI S
    Ultra-Treatment-Resistant Schizophrenia and Clozapine Augmentation.
    J Clin Psychopharmacol. 2023 Feb 1. doi: 10.1097/JCP.0000000000001652.
    PubMed    
    
    
    January 2023
57. SHUKLA A, Nandan NK, Singh LK
    Acute Psychosis After Immunization With Whole-Virion Inactivated COVID-19 Vaccine; A Case Report From Central India.
    J Clin Psychopharmacol. 2023;43:66-67.
    PubMed    
    
    
    
58. DE LIMA DN JR, Costa Filho CWL, Frota IJ, de Oliveira ALB, et al
    alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia: A Randomized Double-Blind Study.
    J Clin Psychopharmacol. 2023;43:39-45.
    PubMed     Abstract available
    
    
    
59. CUOMO A, Aguglia E, Biagini S, Carano A, et al
    Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia.
    J Clin Psychopharmacol. 2023;43:35-38.
    PubMed     Abstract available
    
    
    November 2022
60. KIM K, Kim YS, Joo EJ, Kim EJ, et al
    Clozapine Blood Concentration Predicts Corrected QT-Interval Prolongation in Patients With Psychoses.
    J Clin Psychopharmacol. 2022;42:536-543.
    PubMed     Abstract available
    
    
    
61. CONTRUCCI RR, Heikens M, Beex-Oosterhuis MM
    Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections.
    J Clin Psychopharmacol. 2022;42:608-609.
    PubMed    
    
    
    October 2022
62. DING J, Zhang Y, Zhang Y, Yang L, et al
    Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
    J Clin Psychopharmacol. 2022 Oct 25. pii: 00004714-990000000-00067.
    PubMed     Abstract available
    
    
    
63. JU V, Walkerly A, VandenBerg A, Shobassy A, et al
    New Onset of Seizures and Psychosis in a Patient Who Is Coprescribed Atomoxetine and Bupropion: A Case Report.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00056.
    PubMed    
    
    
    
64. OKADA T, Hori H, Hasegawa N, Murata A, et al
    Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022 Oct 4. pii: 00004714-990000000-00057.
    PubMed    
    
    
    
65. DARWISH M, Bugarski-Kirola D, Passarell J, Owen J, et al
    Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.
    J Clin Psychopharmacol. 2022 Oct 3. pii: 00004714-990000000-00053.
    PubMed     Abstract available
    
    
    September 2022
66. TEODORO T, Nogueira V, Aldeias J, Teles Martins M, et al
    Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00049.
    PubMed    
    
    
    
67. HORIKOSHI S, Miura I, Mui A, Hikichi T, et al
    Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study.
    J Clin Psychopharmacol. 2022 Sep 5. pii: 00004714-990000000-00048.
    PubMed     Abstract available
    
    
    
68. KANE JM
    A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    J Clin Psychopharmacol. 2022;42.
    PubMed     Abstract available
    
    
    
69. SATODIYA RM, Brown VR, Njuguna SW, Bied AM, et al
    A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight.
    J Clin Psychopharmacol. 2022;42:495-499.
    PubMed     Abstract available
    
    
    August 2022
70. ZHAND N, Labelle A, Ghanem D, Gujral P, et al
    Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics.
    J Clin Psychopharmacol. 2022 Aug 17. pii: 00004714-990000000-00044.
    PubMed     Abstract available
    
    
    July 2022
71. TIEN Y, Huang SC
    Aripiprazole-Associated Acute Dystonia During Dose Reduction in Patient With Schizophrenia and Dementia: A Case Report.
    J Clin Psychopharmacol. 2022 Jul 2. pii: 00004714-990000000-00031.
    PubMed    
    
    
    
72. GROVER S, Naskar C, Chakrabarti S
    Factors Associated With Poor Response to Clozapine in Schizophrenia: A Study From Northern India.
    J Clin Psychopharmacol. 2022;42:345-349.
    PubMed     Abstract available
    
    
    
73. GONZALEZ-RODRIGUEZ A, Monreal JA
    Time for Rational Pharmacotherapy in Delusional Disorder: New Targets for Old Clinical Observations.
    J Clin Psychopharmacol. 2022;42:413-414.
    PubMed    
    
    
    
74. BECHARD L, Morasse-Begis M, Corbeil O, Hakim JR, et al
    Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
    J Clin Psychopharmacol. 2022;42:391-395.
    PubMed     Abstract available
    
    
    June 2022
75. KOGURE M, Kanahara N, Kimura M, Hanaoka S, et al
    Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
    J Clin Psychopharmacol. 2022 Jun 17. pii: 00004714-990000000-00026.
    PubMed     Abstract available
    
    
    
76. CHIU CC, Lin C, Chen WY, Chen CR, et al
    Therapeutic Drug Monitoring of Paliperidone in Patients With Schizophrenia in Taiwan.
    J Clin Psychopharmacol. 2022 Jun 14. pii: 00004714-990000000-00023.
    PubMed     Abstract available
    
    
    
77. WANG D, Wei N, Hu F, Li J, et al
    Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.
    J Clin Psychopharmacol. 2022 Jun 10. pii: 00004714-990000000-00019.
    PubMed     Abstract available
    
    
    May 2022
78. GALLAGHER KE, Funaro MC, Woods SW
    Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational Studies.
    J Clin Psychopharmacol. 2022;42:308-314.
    PubMed     Abstract available
    
    
    March 2022
79. YEE CS, Bahji A, Lolich M, Vazquez GH, et al
    Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
    J Clin Psychopharmacol. 2022;42:198-208.
    PubMed     Abstract available
    
    
    
80. FRANKENBURG FR, Malvesti S
    Paliperidone and Edema.
    J Clin Psychopharmacol. 2022;42:225-226.
    PubMed    
    
    
    February 2022
81. TAKAKI M, Yada Y, Sakamoto S, Fujiwara M, et al
    A Decrease of Neutrophils After COVID-19 Vaccination in a Treatment-Resistant Patient With Schizophrenia Taking Clozapine.
    J Clin Psychopharmacol. 2022 Feb 10. pii: 00004714-900000000-98207.
    PubMed    
    
    
    January 2022
82. WANG XY, Chan HY, Lin CH
    Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study.
    J Clin Psychopharmacol. 2022 Jan 6. pii: 00004714-900000000-98219.
    PubMed     Abstract available
    
    
    
83. CINTRON PASTRANA MA, Quintana Aviles E
    Treatment of Refractory Schizophrenia With Clozapine in a Patient With Wolff-Parkinson-White Syndrome.
    J Clin Psychopharmacol. 2022;42:95-96.
    PubMed    
    
    
    
84. HE L, Yu Y, Zhang L, He S, et al
    A Real-World Study of Risk Factors for QTc Prolongation in Schizophrenia Patients Receiving Atypical Antipsychotics.
    J Clin Psychopharmacol. 2022;42:71-74.
    PubMed     Abstract available
    
    
    
85. SMITH RL, Wollmann BM, Kylleso L, Tran TTA, et al
    Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia.
    J Clin Psychopharmacol. 2022;42:43-50.
    PubMed     Abstract available
    
    
    
86. STROMME MF, Mellesdal LS, Bartz-Johannesen CA, Kroken RA, et al
    Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.
    J Clin Psychopharmacol. 2022;42:37-42.
    PubMed     Abstract available
    
    
    
87. GARRIGA M, Mallorqui A, Bernad S, Ruiz-Cortes V, et al
    Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.
    J Clin Psychopharmacol. 2022;42:75-80.
    PubMed     Abstract available
    
    
    
88. BONNET U, Knierim U, Ronge R, Jahn J, et al
    Late-Onset Polyserositis Emerging During Long-Term Clozapine Treatment and Persisting After Clozapine Discontinuation: Is Clozapine Really Innocent?
    J Clin Psychopharmacol. 2022;42:106-107.
    PubMed    
    
    
    
89. ERDOGAN A, Ilhan F
    Risperidone-Associated Acute Laryngeal Dystonia: A Case Report.
    J Clin Psychopharmacol. 2022;42:98-99.
    PubMed    
    
    
    November 2021
90. MAURI MC, Franco G, Minutillo A, Paletta S, et al
    The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data).
    J Clin Psychopharmacol. 2021 Nov 24. pii: 00004714-900000000-98229.
    PubMed     Abstract available
    
    
    
91. RUDA D, Jensen KG, Decara MS, Klauber DG, et al
    CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
    J Clin Psychopharmacol. 2021;41:667-672.
    PubMed     Abstract available
    
    
    
92. WEIZMAN S, Shelef A, Bloemhof Bris E, Stryjer R, et al
    A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.
    J Clin Psychopharmacol. 2021;41:629-631.
    PubMed     Abstract available
    
    
    
93. COMAI S, Fuamba Y, Rivolta MC, Gobbi G, et al
    Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital.
    J Clin Psychopharmacol. 2021;41:623-628.
    PubMed     Abstract available
    
    
    
94. MAKHLOUF AT, Van Alphen MU, Manzano GS, Freudenreich O, et al
    A Seizure After COVID-19 Vaccination in a Patient on Clozapine.
    J Clin Psychopharmacol. 2021;41:689-690.
    PubMed    
    
    
    
95. CELLINI L, De Donatis D, Mercolini L, Panariello F, et al
    Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series.
    J Clin Psychopharmacol. 2021;41:694-696.
    PubMed    
    
    
    
96. OKEYA K, Misawa F, Fujii Y, Takeuchi H, et al
    Olanzapine Reduction From High Dose to Standard Dose: A Retrospective Chart Review.
    J Clin Psychopharmacol. 2021;41:676-680.
    PubMed     Abstract available
    
    
    
97. SELCUK M
    Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report.
    J Clin Psychopharmacol. 2021;41:692-694.
    PubMed    
    
    
    September 2021
98. SRIFUENGFUNG M, Sukakul T, Pummangura C, Srifuengfung S, et al
    Oral Ulcers as an Unpredictable Adverse Reaction to Quetiapine Use in a Patient With Schizophrenia.
    J Clin Psychopharmacol. 2021 Sep 9. pii: 00004714-900000000-98247.
    PubMed    
    
    
    
99. MASHIMA Y, Uchida H, Kinoshita S, Arita Y, et al
    Camptocormia Secondary to Antipsychotic-Associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography: A Case Report.
    J Clin Psychopharmacol. 2021;41:608-610.
    PubMed    
    
    
    
100. CUOMO A, Chioccioli M, Cattaneo CI, Magnani PA, et al
     Effectiveness of Intramuscular Chlorpromazine for Rapid Treatment of Psychomotor Agitation: A Naturalistic, Retrospective, and Observational Study.
     J Clin Psychopharmacol. 2021;41:613-614.
     PubMed    
     
     
     August 2021
101. PEITL V, Badzim VA, Sisko Markos I, Rendulic A, et al
     Improvements of Frontotemporal Cerebral Blood Flow and Cognitive Functioning in Patients With First Episode of Schizophrenia Treated With Long-Acting Aripiprazole.
     J Clin Psychopharmacol. 2021 Aug 26. pii: 00004714-900000000-98248.
     PubMed     Abstract available
     
     
     
102. OGAWA T, Tachikawa H, Shiratori Y, Sodeyama N, et al
     Use of Blonanserin Transdermal Patch in Home Treatment of Schizophrenia: A Case Study.
     J Clin Psychopharmacol. 2021 Aug 23. pii: 00004714-900000000-98251.
     PubMed    
     
     
     
103. LIM M, Li Z, Xie H, Tan BL, et al
     The Effect of Therapeutic Alliance on Attitudes Toward Psychiatric Medications in Schizophrenia.
     J Clin Psychopharmacol. 2021 Aug 13. pii: 00004714-900000000-98260.
     PubMed     Abstract available
     
     
     July 2021
104. 
     Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia: Erratum.
     J Clin Psychopharmacol. 2021;41:507.
     PubMed    
     
     
     
105. AFTAB R, Pereira M, Hewitt J, Whale R, et al
     Effectiveness and Predictors of Discontinuation of Aripiprazole Long-acting Injection: A 12-Month Naturalistic Cohort Study.
     J Clin Psychopharmacol. 2021;41:478-483.
     PubMed     Abstract available
     
     
     
106. GLICK ID, Cerfolio NE, Kamis D, Laurence M, et al
     Domestic Mass Shooters: The Association With Unmedicated and Untreated Psychiatric Illness.
     J Clin Psychopharmacol. 2021;41:366-369.
     PubMed     Abstract available
     
     
     
107. SINKEVICIUTE I, Hugdahl K, Bartz-Johannessen C, Kroken RA, et al
     Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
     J Clin Psychopharmacol. 2021;41:389-396.
     PubMed     Abstract available
     
     
     
108. SUHAS S, Manchegowda S, Venkatasubramanian G, Kumar V, et al
     Clozapine and Oral Contraceptives-Implications Beyond Pharmacokinetics: A Case Report.
     J Clin Psychopharmacol. 2021;41:487-490.
     PubMed    
     
     
     June 2021
109. KOREKI A, Mori H, Nozaki S, Koizumi T, et al
     Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: A Cross-sectional Study.
     J Clin Psychopharmacol. 2021 Jun 4. pii: 00004714-900000000-98299.
     PubMed     Abstract available
     
     
     May 2021
110. SUHAS S, Shivani S, Singh GK, Venkatasubramanian G, et al
     Festina Lente: Betahistine for Clozapine-Associated Weight Gain: A Case Report.
     J Clin Psychopharmacol. 2021;41:332-333.
     PubMed    
     
     
     
111. SUZUKI K, Castelli M, Komaroff M, Starling B, et al
     Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
     J Clin Psychopharmacol. 2021;41:286-294.
     PubMed     Abstract available
     
     
     
112. MATHUR R, Singh J, Sood M
     A Case Report of Clozapine-Associated Stuttering and Amisulpride-Associated Stuttering and Seizure in an Adult on Concurrent Fluoxetine Therapy.
     J Clin Psychopharmacol. 2021;41:330-332.
     PubMed    
     
     
     
113. TIRUPATI S, Gordon T
     Continuation of Treatment With Clozapine After an Episode of Neutropenia.
     J Clin Psychopharmacol. 2021;41:320-322.
     PubMed     Abstract available
     
     
     April 2021
114. GUIMARAES TM, Guimaraes MRC, Oliveira IAF, Leoni RF, et al
     Mononitrate Isosorbide as an Adjunctive Therapy in Schizophrenia: A Randomized Controlled Crossover Trial.
     J Clin Psychopharmacol. 2021 Apr 14. pii: 00004714-900000000-98311.
     PubMed     Abstract available
     
     
     
115. LINDENMAYER JP, Rizvi S
     Augmentation With Pimavanserin in Treatment Refractory Schizophrenia: Case Report.
     J Clin Psychopharmacol. 2021 Apr 13. pii: 00004714-900000000-98312.
     PubMed    
     
     
     March 2021
116. AN H, Fan H, Chen S, Qi S, et al
     Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
     J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98320.
     PubMed     Abstract available
     
     
     
117. WANG J, Hart KL, Qi W, Ardekani BA, et al
     Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia.
     J Clin Psychopharmacol. 2021 Mar 31. pii: 00004714-900000000-98319.
     PubMed     Abstract available
     
     
     
118. REHIMINI S, Goddard KG, Margolese HC
     Exceptionally High Clozapine-Associated Eosinophilia.
     J Clin Psychopharmacol. 2021;41:216-218.
     PubMed    
     
     
     
119. GROVER S, Naskar C, Chakrabarti S
     Does the Starting of Clozapine Influence Coprescription of Other Medications?: A Study From India.
     J Clin Psychopharmacol. 2021;41:148-154.
     PubMed     Abstract available
     
     
     
120. GRIFFIN JM, Woznica E, Gilotra NA, Nucifora FC Jr, et al
     Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge.
     J Clin Psychopharmacol. 2021;41:180-185.
     PubMed     Abstract available
     
     
     
121. YILDIZ MI, Karacam Dogan M, Mutlu E, Abdullayeva L, et al
     All in One: Clozapine-Associated Acute Pancreatitis With Multiple Organ Involvement.
     J Clin Psychopharmacol. 2021;41:214-216.
     PubMed    
     
     
     
122. KHURRAM SK, Ames M, Muniz J
     Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
     J Clin Psychopharmacol. 2021;41:220-221.
     PubMed    
     
     
     
123. MISAWA F, Fujii Y, Takeuchi H
     Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly?: Analysis Based on a Spontaneous Reporting System Database in Japan.
     J Clin Psychopharmacol. 2021;41:206-207.
     PubMed    
     
     
     
124. DANILEWITZ M, Rafizadeh R, Bousman CA
     Successful Clozapine Rechallenge After Suspected Clozapine-Associated Myocarditis: A Case Report.
     J Clin Psychopharmacol. 2021;41:218-220.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.